Moclobemide Film Coated Tablets Market – Antidepressant Therapy for Depression and Anxiety Disorders

The moclobemide film-coated tablets market is a specialized segment of the pharmaceutical industry, providing effective antidepressant therapy for patients with depression, anxiety disorders, and other psychiatric conditions. Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA), offering a favorable safety profile with fewer side effects compared to traditional antidepressants. With rising prevalence of mental health disorders and increasing awareness of treatment options, this market is experiencing steady growth.

The market was valued at USD 400 million in 2024, about USD 400 million in 2025, and is projected to reach roughly USD 600 million by 2035, growing at a CAGR of approximately 4.4%. Growth is driven by the increasing prevalence of depression and anxiety disorders worldwide, growing awareness of mental health issues, rising demand for antidepressants with improved tolerability, development of generic alternatives, and innovations in drug formulation.

By application, depression treatment holds the largest share, reflecting its critical role in managing mood disorders and improving patient outcomes. Anxiety disorder treatment and psychiatric disorders also contribute significantly, each leveraging moclobemide film-coated tablets for effective symptom management and enhanced quality of life.

By dosage form, 10 mg, 15 mg, and 30 mg tablets cater to varying patient needs and therapeutic requirements, with each sub-segment demonstrating distinct growth potential. The overall market is expected to experience steady expansion across these dosage forms, catering to the increasing prevalence of conditions treated by moclobemide.

End users are led by hospitals, which handle the majority of psychiatric cases and complex treatment plans. Clinics and pharmacies also contribute significantly, each leveraging moclobemide film-coated tablets for accessible care and medication procurement, enhancing adherence to prescribed therapies.

By distribution channel, online pharmacies are experiencing rapid growth due to convenience and accessibility, particularly for patients in remote areas. Retail pharmacies remain significant, often serving as the first point of contact for consumers seeking prescription medications. Hospital pharmacies are also essential, providing patients with necessary medications during treatment.

Regionally, North America leads with over 30% of the global market, supported by advanced healthcare infrastructure and growing awareness of mental health treatments. Europe follows closely, driven by increasing prescriptions and strong emphasis on mental health awareness. Asia-Pacific is expected to exhibit significant growth, fueled by rising healthcare expenditures and expanding patient populations.

Key players include Sun Pharmaceutical Industries Ltd, Sandoz International GmbH, Fujifilm Corporation, Wockhardt Limited, Mylan N.V., Stada Arzneimittel AG, Zhejiang Huahai Pharmaceutical Co Ltd, Aurobindo Pharma Ltd, H Lundbeck A/S, Rottapharm Madaus S.p.A., Aceto Corporation, Boehringer Ingelheim International GmbH, Sihuan Pharmaceutical Holdings Group Ltd, Novartis AG, and Teva Pharmaceutical Industries Ltd. Strategies focus on enhancing product quality, optimizing production processes, and forming strategic partnerships to expand market reach.

Read more: Moclobemide Film-Coated Tablets Market | Size & Outlook 2035

People Also Ask

Q1. What are moclobemide film-coated tablets used for?
Moclobemide film-coated tablets are used for the treatment of depression, anxiety disorders, and other psychiatric conditions, offering a reversible inhibitor of monoamine oxidase A (RIMA) with improved tolerability and fewer side effects compared to traditional antidepressants.

Q2. Which region leads the moclobemide film-coated tablets market?
North America leads due to advanced healthcare infrastructure and growing awareness of mental health treatments, while Asia-Pacific is emerging rapidly, driven by rising healthcare expenditures and expanding patient populations.

Tags: moclobemide, film-coated tablets, antidepressant, depression treatment, anxiety disorders, psychiatric disorders